NEW YORK (GenomeWeb) – Taconic Biosciences said today that it has acquired a worldwide, nonexclusive license to a novel CRISPR genome-editing technology from the University of Nebraska.
Called Easi-CRISPR — short for efficient additions with ssDNA inserts-CRISPR — the technology is designed to enable more efficient targeted DNA cassette insertion in the engineering of animal models.
Under the terms of the deal, Taconic can generate and sell rodent models using the Easi-CRISPR technology. Additional terms were not disclosed.
"Combining the speed of CRISPR with larger genetic insertions allows complex projects typically requiring homologous recombination techniques to reduce project timelines by six months," John Couse, vice president of scientific services at Taconic, said in a statement.
Last year, Taconic — which provides gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR-Cas9, pronuclear injection, and homologous recombination technologies — acquired a nonexclusive license to CRISPR-Cas9 technology from ERS Genomics.